NeoCura is a high-tech enterprise focused on the development of innovative RNA-based therapies and drug research, leveraging advanced AI technologies. The company has established a comprehensive multi-omics big data collection platform and a robust bioinformatics database, which facilitate in-depth drug target discovery and fully automated drug design. This infrastructure supports the advancement of their RNA technology platform and drug research initiatives, with leading research and production centers located in Beijing, Shenzhen, and Guangzhou, aimed at meeting clinical demands and enhancing pipeline development.

The company emphasizes the integration of AI throughout the entire RNA drug development process, which accelerates both drug research and technological upgrades. NeoCura boasts a highly complementary team of experts in tumor immunology, RNA delivery, molecular engineering, and artificial intelligence, enabling them to consolidate top-tier resources from both domestic and international research, industry, and clinical sectors. Their focus includes multiple first-in-class research pipelines targeting tumor vaccines, tumor immune modulation, and viral vaccines, positioning NeoCura as a leader in the RNA innovation drug sector.

China

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

NeoCura

Company Details